Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report.
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.
In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report.
